| Also known as |
Tamiflu |
| Blood pressure |
No significant effects |
| Chemical name |
(3R,4R,5S)-4-acetylamino-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid, ethyl ester, phosphate (1:1) |
| Dosage (medical) |
75 mg twice daily for 5 days |
| Dosage (sports) |
Not applicable |
| Effects |
Reduces severity and duration of influenza symptoms |
| Formula |
C16H28N2O4 В· H3PO4 |
| Half-life |
6-10 hours |
| Hepatotoxicity |
Low risk |
| Lab Test |
Not typically required for monitoring |
| Main action |
Neuraminidase inhibitor |
| Side effects |
Nausea, vomiting, headache, and rare cases of severe skin reactions and neuropsychiatric events |
| Storage conditions |
Store at room temperature away from moisture and heat |
| Strength |
75mg |
| Substance class |
Antiviral |
| Trade name |
Tamiflu |
| Use in sports |
Not typically used in sports |
| Water Retention |
None |
| Manufacturer |
Cipla Ltd. |
| Packing |
10 caps/blister |
